NCT04985357撤回不适用
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- Travera Inc
- 入组人数
- 630
- 主要终点
- Best overall response (BOR)
研究概览
简要总结
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sample collection or biopsy of tumor is clinically indicated as part of SOC
- •Prior to preceding onto therapy for treatment
排除标准
- •Unable to obtain sufficient sample
结局指标
主要结局
Best overall response (BOR)
时间窗: up to 24 months
The best overall response to therapy over 24 months will be captured for correlation with test outcomes.
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Self-adherent Absorbent Silver Dressing in Adults After Hip or Knee ArthroplastyArthroplasties, Hip ReplacementArthroplasties, Knee ReplacementNCT03016078Molnlycke Health Care AB21
已完成
1 期
Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT00651781PETHEMA Foundation40
已完成
4 期
Telithromycin in Respiratory Tract InfectionsRespiratory Tract InfectionsNCT00261105Sanofi
招募中
不适用
Massed Prolonged Exposure for PTSD in Substance Use TreatmentStress Disorders, Post-TraumaticSubstance Use DisordersNCT06296186Veterans Medical Research Foundation200
尚未招募
4 期
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with MethotrexateRheumatoid Arthritis (RA)Methotrexate Induced NephrotoxicityMethotrexate Adverse ReactionNCT06641128Tanta University44